The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF-β receptor inhibitor that can potentially disrupt the TGF-β signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. “Both advanced colorectal cancer and acute myeloid leukemia continue to be defined by high unmet needs in the relapse/refractory setting,” said Jennifer Chow, Chimeric CEO and Managing Director. “Dosing of the first patient in this trial is a meaningful step towards realizing the potential of CHM 0201 in providing better options for treatment and care to these patients.” The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.
CHM is not actively running / controlling the trial, that way could be due to Holidays as you mentioned.
GLTA
CHM Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)